NASDAQ:QDEL

QuidelOrtho (QDEL) Stock Forecast, Price & News

$71.56

-0.07 (-0.10%)

(As of 09/25/2023 ET)

Compare

Today's Range: $70.83
▼
$72.08
50-Day Range: $71.56
▼
$88.63
52-Week Range: $66.88
▼
$102.00

Volume: 295,611 shs
Average Volume: 460,696 shs
Market Capitalization: $4.78 billion

P/E Ratio: 108.43
Dividend Yield: N/A
Price Target: $119.83

QuidelOrtho MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 67.5% Upside
$119.83 Price Target
Short Interest: Healthy
3.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.84
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 9.07%
From $4.96 to $5.41 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.91 out of 5 stars

Medical Sector

55th out of 963 stocks

Diagnostic Substances Industry

1st out of 13 stocks

3.4

Analyst's Opinion

Consensus Rating
QuidelOrtho has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $119.83, QuidelOrtho has a forecasted upside of 67.5% from its current price of $71.56.
Amount of Analyst Coverage
QuidelOrtho has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.71% of the outstanding shares of QuidelOrtho have been sold short.
Short Interest Ratio / Days to Cover
QuidelOrtho has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in QuidelOrtho has recently decreased by 6.06%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
QuidelOrtho does not currently pay a dividend.
Dividend Growth
QuidelOrtho does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
QuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for QuidelOrtho is -2.61.

3.2

News and Social Media Coverage

News Sentiment
QuidelOrtho has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for QuidelOrtho this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, QuidelOrtho insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.20% of the stock of QuidelOrtho is held by insiders.
Percentage Held by Institutions
93.87% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for QuidelOrtho are expected to grow by 9.07% in the coming year, from $4.96 to $5.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of QuidelOrtho is 108.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.55.
Price to Earnings Ratio vs. Sector
The P/E ratio of QuidelOrtho is 108.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.33.
Price to Book Value per Share Ratio
QuidelOrtho has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

QDEL Price History

30 days | 90 days | 365 days | Advanced Chart

QDEL Stock News Headlines

September 26, 2023 | money.usnews.com

QuidelOrtho Corporation

September 21, 2023 | finance.yahoo.com

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

September 26, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

September 21, 2023 | finance.yahoo.com

Should You Add QuidelOrtho (QDEL) to Your Portfolio?

September 20, 2023 | americanbankingnews.com

QuidelOrtho's (QDEL) Outperform Rating Reaffirmed at Royal Bank of Canada

September 19, 2023 | benzinga.com

Where QuidelOrtho Stands With Analysts

September 19, 2023 | msn.com

RBC Capital Reiterates QuidelOrtho (QDEL) Outperform Recommendation

September 19, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Regulus (RGLS), Ambrx Biopharma (AMAM)

September 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 16, 2023 | americanbankingnews.com

Zacks Research Equities Analysts Reduce Earnings Estimates for QuidelOrtho Co. (NASDAQ:QDEL)

August 28, 2023 | finance.yahoo.com

QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 17, 2023 | msn.com

Down -14% in 4 Weeks, Here's Why You Should You Buy the Dip in QuidelOrtho (QDEL)

August 15, 2023 | markets.businessinsider.com

Analyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's Why

August 10, 2023 | seekingalpha.com

QuidelOrtho Corporation 2023 Q2 - Results - Earnings Call Presentation

August 9, 2023 | msn.com

QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised

August 8, 2023 | finance.yahoo.com

QuidelOrtho (QDEL) Reports Q2 Earnings: What Key Metrics Have to Say

August 8, 2023 | finance.yahoo.com

QuidelOrtho Reports Second Quarter 2023 Financial Results

August 7, 2023 | markets.businessinsider.com

Craig-Hallum Keeps Their Buy Rating on QuidelOrtho (QDEL)

July 24, 2023 | finance.yahoo.com

QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings

July 24, 2023 | msn.com

Wall Street Analysts Believe QuidelOrtho (QDEL) Could Rally 29.87%: Here's is How to Trade

July 19, 2023 | finance.yahoo.com

The three-year shareholder returns and company earnings persist lower as QuidelOrtho (NASDAQ:QDEL) stock falls a further 3.2% in past week

July 18, 2023 | finance.yahoo.com

QuidelOrtho to Report Second Quarter 2023 Financial Results

July 18, 2023 | finance.yahoo.com

Are Investors Undervaluing QuidelOrtho (QDEL) Right Now?

July 13, 2023 | seekingalpha.com

QuidelOrtho: Mapping A Future As Covid Revenues Move To Endemic Phase

July 13, 2023 | seekingalpha.com

QuidelOrtho: A Tough Call To Make Right Now

July 4, 2023 | wsj.com

QuidelOrtho Corp.

June 12, 2023 | finance.yahoo.com

Declining Stock and Decent Financials: Is The Market Wrong About QuidelOrtho Corporation (NASDAQ:QDEL)?

See More Headlines

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Company Calendar

Last Earnings: 8/08/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:QDEL
CUSIP: 74838J10
CIK: 353569
Web: www.quidel.com
Phone: (800) 874-1517
Fax: 858-453-4338
Employees: 7,000
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $119.83
High Stock Price Forecast: $173.00
Low Stock Price Forecast: $85.00
Forecasted Upside/Downside: +67.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.66
Trailing P/E Ratio: 108.43
Forward P/E Ratio: 14.43
P/E Growth: N/A
Net Income: $548.70 million
Net Margins: 1.43%
Pretax Margin: 2.15%
Return on Equity: 7.65%
Return on Assets: 4.33%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 1.66
Quick Ratio: 0.97

Sales & Book Value

Annual Sales: $3.27 billion
Price / Sales: 1.46
Cash Flow: $18.21 per share
Price / Cash Flow: 3.93
Book Value: $74.71 per share
Price / Book: 0.96

Miscellaneous

Outstanding Shares: 66,790,000
Free Float: 65,322,000
Market Cap: $4.78 billion
Optionable: Optionable
Beta: 0.27

Social Links

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Douglas C. Bryant (Age 65)
Pres, CEO & Director
Comp: $4.82M

Mr. Joseph M. Busky CPA (Age 55)
Chief Financial Officer
Comp: $1.47M

Mr. Robert J. Bujarski J.D. (Age 54)
Exec. VP & COO
Comp: $2.62M

Ms. Michelle A. Hodges (Age 63)
Sr. VP & Gen. Counsel
Comp: $1.8M

Dr. Werner Kroll Ph.D. (Age 66)
Sr. VP of R&D
Comp: $1.25M

Ms. Louise M. Brandy
Sr. VP & Chief Information Officer

Mr. Patrick E. Klein
Chief Admin. Officer

Ruben Argueta
Director of Investor Relations

Mr. William J. Ferenczy (Age 67)
Point of Care Bus. Unit Leader

Mr. Michael S. Iskra (Age 53)
Exec. VP & Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

QDEL Stock - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" QDEL shares.
View QDEL analyst ratings or view top-rated stocks.
What is QuidelOrtho's stock price forecast for 2023?: 5 equities research analysts have issued 12-month target prices for QuidelOrtho's stock. Their QDEL share price forecasts range from $85.00 to $173.00. On average, they anticipate the company's stock price to reach $119.83 in the next twelve months. This suggests a possible upside of 67.5% from the stock's current price.
View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts.
How have QDEL shares performed in 2023?: QuidelOrtho's stock was trading at $85.67 at the beginning of the year. Since then, QDEL shares have decreased by 16.5% and is now trading at $71.56.
View the best growth stocks for 2023 here.
When is QuidelOrtho's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our QDEL earnings forecast.
How were QuidelOrtho's earnings last quarter?: QuidelOrtho Co. (NASDAQ:QDEL) released its earnings results on Tuesday, August, 8th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.23 by $0.03. The company had revenue of $665.10 million for the quarter, compared to analyst estimates of $615.11 million. QuidelOrtho had a net margin of 1.43% and a trailing twelve-month return on equity of 7.65%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.11 earnings per share.
What ETFs hold QuidelOrtho's stock?: ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Ballast Small/Mid Cap ETF (MGMT) and Simplify Health Care ETF (PINK).iShares U.S. Medical Devices ETF (IHI).
What guidance has QuidelOrtho issued on next quarter's earnings?: QuidelOrtho updated its FY 2023 earnings guidance on Wednesday, August, 9th. The company provided earnings per share (EPS) guidance of $4.85-$5.30 for the period, compared to the consensus estimate of $5.34. The company issued revenue guidance of $2.88 billion-$3.08 billion, compared to the consensus revenue estimate of $3.00 billion.
What is Doug Bryant's approval rating as QuidelOrtho's CEO?: 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?: Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).
What is QuidelOrtho's stock symbol?: QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL."
Who are QuidelOrtho's major shareholders?: QuidelOrtho's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.50%), ArrowMark Colorado Holdings LLC (4.83%), Senvest Management LLC (4.65%), State Street Corp (2.33%), JPMorgan Chase & Co. (1.79%) and Geode Capital Management LLC (1.27%). Insiders that own company stock include Charles P Slacik, Douglas C Bryant, Mary Lake Ph D Polan, Werner Kroll, William J Ferenczy and William J Ferenczy.
View institutional ownership trends.
How do I buy shares of QuidelOrtho?: Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is QuidelOrtho's stock price today?: One share of QDEL stock can currently be purchased for approximately $71.56.
How much money does QuidelOrtho make?: QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $4.78 billion and generates $3.27 billion in revenue each year. The company earns $548.70 million in net income (profit) each year or $0.66 on an earnings per share basis.
How many employees does QuidelOrtho have?: The company employs 7,000 workers across the globe.
How can I contact QuidelOrtho?: QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (800) 874-1517, via email at rargueta@quidel.com, or via fax at 858-453-4338.

This page (NASDAQ:QDEL) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial